Back to mobile site

Pacira Pharma (PCRX) PT Raised to $64 At Needham

July 6, 2020 7:27 AM EDT Send to a Friend
Needham & Company analyst, Serge Belanger, reiterated a Buy rating on shares of Pacira Pharmaceuticals (NASDAQ: PCRX) and raised the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login